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Abstract
Background: Potassium depletion is common in hospitalized patients and can cause serious complications such as
cardiac arrhythmias. In the intensive care unit (ICU) the majority of patients require potassium suppletion. However,
there are no data regarding the optimal control target in critically ill patients. After open-heart surgery, patients
have a strongly increased risk of atrial fibrillation or atrial flutter (AFF). In a novel trial design, we examined if in
these patients different potassium control-targets within the normal range may have different effects on the
incidence of AFF.
Methods/Design: The “computer-driven Glucose and potassium Regulation program in Intensive care Patients
with COMparison of PotASSium targets within normokalemic range (GRIP-COMPASS) trial” is a single-center
prospective trial in which a total of 1200 patients are assigned to either a potassium control-target of 4.0 mmol/L
or 4.5 mmol/L in consecutive alternating blocks of 50 patients each. Potassium levels are regulated by the
computer-assisted potassium suppletion algorithm called GRIP-II (Glucose and potassium regulation for Intensive
care Patients). Primary endpoint is the in-hospital incidence of AFF after cardiac surgery. Secondary endpoints are:
in-hospital AFF in medical patients or patients after non-cardiac surgery, actually achieved potassium levels and
their variation, electrolyte and glucose levels, potassium and insulin requirements, cumulative fluid balance, (ICU)
length of stay, ICU mortality, hospital mortality and 90-day mortality.
Discussion: The GRIP-COMPASS trial is the first controlled clinical trial to date that compares potassium targets.
Other novel methodological elements of the study are that it is performed in ICU patients where both targets are
within the normal range and that a computer-assisted potassium suppletion algorithm is used.
Trial registration: NCT 01085071 at ClinicalTrials.gov
Background
Potassium disorders occur frequently in hospitalized
patients [1,2] and it has long been known that extreme
potassium values can cause life-threatening complica-
tions, especially in critically ill patients [3,4]. However,
the effects on outcome of less pronounced differences in
the potassium concentration, that occur much more fre-
quently, are not known.
As is the case with most laboratory parameters,
plasma potassium values are considered as “normal”
when they equal those observed in a healthy reference
population. Although desirable levels for some labora-
tory parameters in critically patients may equal healthy
reference levels, for others, such as hemoglobin, albumin
or calcium, this is not the case [5-7]. Although potas-
sium is administered to the majority of intensive care
unit (ICU) patients, the optimal level in critically ill
patients has never been investigated. There are no pro-
spective trials concerning potassium regulation and only
a few observational studies and reviews that describe the
treatment once severe potassium disorders have
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developed [3,8,9]. Potassium has recently been involved
in the debate on the disparate results of the Leuven [10]
and NICE-SUGAR [11] trials that both compared glu-
cose control targets, since the outcome of tight glucose
control might be affected by potentially insufficiently
controlled potassium levels [12].
Potassium regulation in the critically ill patient can be
performed by titrated continuous potassium infusion.
To avoid hyper- and hypokalemia, regular plasma potas-
sium measurements and subsequent adjustments of the
infusion rate are necessary [13-16]. To achieve two tar-
get values within a narrow range an effective potassium
regulation protocol is mandatory. For safety and effi-
ciency, computerized protocols appear to be superior
over paper protocols [17-19]. In our ICU we have
implemented an integrated computer-assisted program
for both glucose and potassium regulation that is called
GRIP-II (Glucose and potassium Regulation for Inten-
sive care Patients) [20-22]. This program provides a
recommendation on the potassium and insulin infusion
rates and the time to the next potassium and glucose
measurement. These recommendations are mainly based
on the current potassium and glucose levels and analysis
of their trend over time. In a before-after study compar-
ing GRIP-II potassium control with physician-driven
potassium control, potassium control improved with a
significantly reduced number of hypokalemic and hyper-
kalemic events [20]. In the latter study the GRIP-II pro-
gram aimed for a potassium level in the middle of the
normal range of 3.5-5.0 mmol/L, i.e 4.3 mmol/L. How-
ever, it is not known what the effects would be when
the target would be slightly different, i.e in normal-low
or normal-high target range.
Potassium is the main intracellular cation of the body.
The intracellular to extracellular potassium ratio affects
both the fluid balance and the resting membrane poten-
tial. The reference plasma potassium ranges from 3.5 to
5.0 mmol/L. Levels below 3.0 mmol/L or above 6.0
mmol/L can cause serious symptoms of which cardiac
arrhythmias are the most frequently observed [4]. After
cardiac surgery (especially valvular surgery) postopera-
tive atrial fibrillation is one of the most common com-
plications with a reported incidence of 10-50%. It is
associated with adverse outcome and despite new treat-
ment strategies the incidence remains high [23-26].
After a potassium load, the intracellular compartment
acts as the primary buffer. A potassium shift from extra-
cellular to intracellular is caused by increased activity of
the Na-K-ATPase pump, which can be directly stimu-
lated by an increase in plasma potassium, insulin,
catecholamines, aldosterone and alkalosis [27-29]. The
most important organs in the homeostasis of potassium
are the kidneys as they normally excrete or reabsorb
potassium according to the overall potassium balance
[30]. There is some evidence that a normal-high plasma
potassium level is preferable in several cardiovascular
states [31-33]. However, the optimal potassium level in
the critically ill patient, who may be especially prone to
the adverse effect of potassium derangements, has never
been investigated prospectively. A cautious approach
towards finding best target levels for potassium seems
justified given the problematic discussions over optimal
glucose targets in ICU patients [10,12]. A computer-
assisted potassium regulation program such as GRIP-II
provides the opportunity to perform a clinical trial to
safely and efficiently compare two potassium targets
within the normal range.
In this prospective phase 4 trial we will compare the
effect of two different potassium control-target values
that are both within the reference range of 3.5 - 5.0
mmol/L. In the NLP (Normal-Low Potassium) trial arm
a normal-low potassium level of 4.0 mmol/L is aimed
for, while in the NHP (Normal-High Potassium) trial
arm a normal-high potassium level of 4.5 mmol/L is
aimed for. We hypothesize that both physiological and
pathophysiological differences may exist between the
normal-low and the normal-high potassium control
targets. In the study all patients are allocated to either
the 4.0 or 4.5 mmol/L control target in alternating
blocks of patients.
The GRIP-COMPASS trial thus constitutes a novel
trial in a number of aspects. It is the first clinical trial to
assess the effect of different potassium target levels.
Also it is the first trial to compare two control-targets
that are both within the reference range in critically ill
patients. Furthermore this trial compares two treatment
strategies that both are executed by a computer-based
potassium suppletion algorithm.
Methods/Design
The GRIP-COMPASS trial is a single-center, prospective
trial with alternating blocks of patients with blinded eva-
luation of the primary endpoint. Twelve hundred
patients are assigned to the NLP control-target of 4.0
mmol/L or the NHP control-target of 4.5 mmol/L at
ICU admission (Figure 1). Allocation to an arm is alter-
nated in blocks of approximately 50 patients until 1200
patients are included, resulting in 24 blocks (Figure 2).
Informed consent for inclusion into one of the two
study arms was waived by our institutional review board
since in both the NLP arm and the NHP arm standard
potassium treatment is involved with the only difference
that the two therapeutic strategies aim at differing nor-
mal levels.
The study will be performed in a 14-bed thoracic-ICU
(closed-format) of a tertiary university teaching hospital.
The institutional medical ethics committee of the
University Medical Center of Groningen approved the
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Figure 1 The GRIP-COMPASS flow-chart. ICU, intensive care unit; GRIP II, glucose and potassium regulation for intensive care patients.
Figure 2 Planned patient allocation scheme. To create two comparable groups while reducing bias from various time-dependent system
effects the GRIP computer is instructed to regularly alternate between the targets of 4.0 and 4.5 mmol/L. The goal is to include 50 patients in
each block, where the precise timing of a block change may also depend on logistic factors.
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study (METc 2009/096). The trial protocol has been
registered at ClinicalTrials.gov (NCT 01085071).
Inclusion
All patients admitted to the thoracic ICU are considered
eligible for inclusion. Excluded are those patients who
do not have a central venous catheter or an enteral
feeding tube because such patients are not entered into
the GRIP-II program for potassium regulation since
they cannot receive continuous potassium administra-
tion to the extent that is regularly necessary. Only rarely
will patients be excluded for this reason. Immediately
after admission a patient is assigned a potassium con-
trol-target that remains unchanged for that patient until
discharge to the general ward. The general characteris-
tics of the population admitted to the thoracic ICU are
summarized in table 1. The majority of patients (~75%)
are admitted after cardiac surgery, i.e. coronary artery
bypass surgery (CABG) and/or valve repair.
Potassium regulation
Potassium will be regulated by the computer-assisted deci-
sion support system called GRIP-II. This nurse-centered
system for both potassium and glucose control was imple-
mented at our ICU in 2004 to improve safety and effi-
ciency. It is, to our knowledge, the first computer-assisted
protocol for both glucose and potassium regulation. Both
the design and results of both the glucose and potassium
algorithm in a large and diverse cohort of ICU patients
have been published previously [20-22]. GRIP-II provides
a recommendation for the potassium and insulin infusion
rate based the patients’ potassium and glucose levels and
the trend over time. It also gives an advice on the time-
interval to the next potassium (and glucose) measurement
and monitors if this measurement is performed on time.
The average required number of point-of-care measure-
ments per patient per day is 5.6, which is low compared to
other computer-assisted glucose protocols [34,35].
Depending on the assigned group (NLP or NHP)
GRIP-II will aim for a potassium control-target of 4.0
mmol/L or 4.5 mmol/L. The glucose target ranges are
the same for both groups (4.0-7.5 mmol/L). Given the
proximity of the targets of the NLP-arm and the NHP-
arm that both lie comfortably within the reference range
and since the spread in potassium levels actually achieved
by GRIP-II was sufficiently small (median 4.3 with an
interquartile range of 4.1-4.5 mmol/L) potassium levels
for both trial arms are expected to stay within the refer-
ence range as well as would be the case without GRIP-II.
Both potassium and glucose are measured in arterial
blood samples of 0.5 ml lithium-heparin anticoagulated
blood using the ABL-800 series point-of-care analyser
(Radiometer Copenhagen, Denmark) that is present on in
the ICU. Potassium chloride is administered continuously
by syringe pump either parenterally by central venous
catheter or enterally. To minimize dosing errors it is admi-
nistered in a “one-to-one” 1 mmol/ml solution. Potassium
chloride suppletion in critically ill patients is efficient and
safe in a dose-dependent and predictable way (indepen-
dent of the use of diuretics or the kidney function)
[15,16,36]. The maximum administration rate advised by
GRIP-II is 20 mmol/hour. When a higher infusion rate is
required, the attending physician can decide to administer
more than 20 mmol/hour. Magnesium is supplemented at
30 mmol/day in patients after cardiac surgery [9]. In non-
cardiac surgery patients, magnesium is only suppleted
when total magnesium levels are <0.80 mmol/L.
Primary endpoint
The primary endpoint is the incidence of in-hospital
atrial fibrillation or atrial flutter (denoted by AFF), con-
firmed by a 12-lead electrocardiogram (ECG), in patients
after cardiac surgery. The reference period over which
this primary endpoint is determined is the first 7 days
post-surgery, or until hospital discharge if the patient is
discharged earlier. The presence of AFF is established
by evaluation of all electrocardiograms by independent




- AFF that develops more than 7 days post-surgery
and until hospital discharge.




Age (years), median (IQR) 66 (57-74)
Male sex 69%










Baseline characteristics of a recent cohort of 500 patients that were admitted
to the thoracic ICU, to provide an impression of the expected patient
population in the GRIP-COMPASS trial. The incidence of AFF was observed in
a subgroup of 150 consecutive cardiac surgery patients. Abbreviations used in
table: ICU intensive care unit; IQR interquartile range; APACHE II acute
physiology and chronic health evaluation II score; AFF atrial fibrillation and
atrial flutter.
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- AFF in patients who do not undergo cardiac
surgery during ICU stay, the first week after ICU
discharge, until hospital discharge.
- The time course of the incidence of AFF (in
cardiac-surgery patients and total patient group).
- The incidence of other serious arrhythmias that
require immediate medical intervention (in cardiac-
surgery patients and total patient group).
- Time that potassium is in the 3.5-5.0 mmol/L
reference range during ICU-admission (in cardiac-
surgery patients and total patient group).
- The occurrence of distinct hypokalemia (i.e potas-
sium <2.8 mmol/L) and distinct hyperkalemia (i.e.
potassium >6.0 mmol/L) in cardiac-surgery patients
and the total patient group, also a safety endpoint.
- Level of glucose control and insulin requirements
during ICU admission.
- Biochemical disturbances of electrolytes (sodium,
magnesium and calcium), blood gas analysis, lactate
and renal function (creatinine, urea) during hospital
admission (total patient group).
- Cumulative fluid balance during ICU admission
(patients admitted to the ICU for more than 5 days).
- ICU and hospital length of stay (in cardiac-surgery
patients and total patient group).
- ICU-mortality and hospital mortality (in cardiac-
surgery patients and total patient group, also a safety
endpoint) as well as 90-day, and 1 year mortality.
In addition to the cardiac surgery group and the total
patient group, the following subgroups will also be com-
pared:
- Patients who underwent CABG with the use of
cardiopulmonary bypass versus patients who under-
went CABG without cardiopulmonary bypass.
- Patients with a history of AFF prior to surgery ver-
sus patients without a history of AFF prior to
surgery.
Data collection
Baseline patient characteristics are collected at ICU
admission (age, sex, length, weight, medical history,
medication use, reason of admission). If a patient under-
goes (cardiac) surgery, data concerning the procedure
and the duration of the procedure (and the time on car-
diopulmonary bypass) are collected. For cardiac surgery
patients the EuroSCORE model for operative risk strati-
fication is calculated [37]. In non-cardiac surgery
patients the APACHE II score is used [38].
This trial requires no specific tests or procedures that
are not regularly performed. Daily laboratory tests and
blood gas analysis (daily at the ICU, in the general ward
only when deemed necessary by the physician) are all
part of standard care. During ICU admission all patients
are under continuous rhythm monitoring (3-lead) and a
12-lead ECG is done at admission (in cardiac-surgery
patients also after 24 and 48 hours), and is repeated
when arrhythmias or other complications occur or are
suspected. At the general ward a the rhythm is checked
regularly and a 12-lead ECG is performed at admission,
when deemed necessary by the attending physician, and
at discharge. When a patient is prone for severe arrhyth-
mias, continuous monitoring by telemetry is continued at
the general ward. All in-hospital ECGs of the included
patients are evaluated by the physicians at the ICU and
the general ward as well as by independent cardiologists
who are blinded for the potassium control-targets.
Potassium and glucose control data (potassium and glu-
cose levels, amount of potassium chloride and insulin
administration, number of measurements per day) are
automatically stored by the GRIP-II program. All other
laboratory tests are stored in the hospital information sys-
tem. ICU-parameters such as the amount of fluid adminis-
tered, the use of vasoactive drugs, anti-arrhythmic drugs,
diuresis, and the fluid balance are monitored and col-
lected. Minor complications and major complications (e.g.
death, stroke, myocardial infarction, organ failure and
major bleeding complications) are recorded. Mortality is
recorded for the ICU, during hospitalisation and at 90-
days. Follow-up information will be obtained from hospital
records and the central personal records database.
Sample size calculation
Because the incidence of AFF in patients after cardiac
surgery is the primary endpoint, the incidence recently
measured in these patients and the expected potential
difference in this incidence between the NLP and NHP
groups were the main determinants of the power analy-
sis. In a pilot study of 150 consecutive patients admitted
after open-heart surgery (CABG and/or valve replace-
ment) during a 3-month period, we observed that 50%
developed postoperative AFF at the ICU or at the ward.
To detect a 10% reduction in the incidence of AFF, with
a two-sided level of significance of 5% and a power of
80%, 2 × 400 cardiac surgery patients should be
included. Assuming that approximately 75% of the
admitted patients will undergo cardiac surgery and with
a 10% margin for excluded patients we arrived at a tar-
get number of 1200 consecutive patients admitted to
the ICU to be included.
In a previous analysis of potassium regulation with
GRIP-II, patients reached a stable potassium level within
12 hours with a mean ± standard deviation (SD) level of
4.25 ± 0.36 mmol/L [20]. When we assume that GRIP-II
maintains this level of accuracy, then a significant differ-
ence in plasma potassium between the NLP and NHP
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groups will be found with less than 50 patients. Thus we
do expect to easily detect very significant differences in
the potassium levels between the NLP and NHP groups.
Statistical analysis
To compare groups, the Student’s t test (normally dis-
tributed variables), the Mann-Whitney U test (other
continuous variables) or Fisher’s exact test (categorical
variables) will be used when appropriate. The level of
potassium control will be expressed as the time within
the normokalemic range (3.5 - 5.0 mmol/L) divided by
the total time spent on the ICU.
In multivariate analysis we will investigate the interac-
tion with glucose, the amount of administered insulin,
sodium and magnesium. A two-sided P value of <0.05
will be considered significant. The Statistical package for
the social sciences (SPSS) version 16.0 will be used for
all statistical analysis.
Conclusion
The GRIP-COMPASS trial is a single-center, prospec-
tive, controlled trial with an alternating patient design
to compare the effect of two different potassium con-
trol-targets that are both within the normal range in
1200 ICU patients. A validated computer-assisted potas-
sium regulation algorithm has an indispensable role in
carrying out this large trial. The primary outcome mea-
sure will be the incidence of atrial fibrillation and flutter
in patients after cardiac surgery.
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